SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Boman Kurt) "

Sökning: WFRF:(Boman Kurt)

  • Resultat 1-10 av 189
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Boman, Kurt, et al. (författare)
  • Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy.
  • 2010
  • Ingår i: Clinical and applied thrombosis/hemostasis. - 1076-0296. ; 16:2, s. 146-152
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVES: To compare the effects of the beta-blocker atenolol with the angiotensin receptor blocker (ARB) losartan on plasma tissue-type plasminogen activator (tPA) activity and mass concentration, plasminogen activator inhibitor-1 (PAI-1) activity, tPA/PAI-1 complex, and von Willebrand factor (VWF). DESIGN: A prespecified, explorative substudy in 22 patients with hypertension and left ventricular hypertrophy (LVH) performed within randomized multicenter, double-blind prospective study. RESULTS: After a median of 36 weeks of treatment, there were significant differences between the treatment groups, atenolol versus losartan, in plasma median levels of tPA mass (11.9 vs 7.3 ng/mL, P = .019), PAI-1 activity (20.7 vs 4.8 IU/mL, P = .030), and tPA/PAI-1 complex (7.1 vs 2.5 ng/mL, P = .015). In patients treated with atenolol, median levels of tPA mass (8.9-11.9 ng/mL, P = .021) and VWF (113.5%-134.3%, P = .021) increased significantly, indicating a change toward a more prothrombotic state. No significant changes occurred in the losartan group. CONCLUSION: Losartan treatment was associated with preserved fibrinolytic balance compared to a more prothrombotic fibrinolytic and hemostatic state in the atenolol group. These findings suggest different fibrinolytic and hemostatic responses to treatment in hypertensive patients with LVH.
  •  
2.
  • Rautio, Aslak, et al. (författare)
  • The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events : Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial
  • 2017
  • Ingår i: Diabetes & Vascular Disease Research. - Sage Publications. - 1479-1641. ; 14:4, s. 345-352
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction: Fibrinolytic factors, plasminogen activator inhibitor-1, tissue plasminogen activator, tissue plasminogen activator/plasminogen activator-complex and the haemostatic factor von Willebrand factor are known markers of cardiovascular disease. Their plasma levels are adversely affected in patients with dysglycaemia, and glucose normalization with insulin glargine might improve the levels of these factors. Methods: Prespecified Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial (ClinicalTrials.gov number, NCT00069784). Tissue plasminogen activator activity, tissue plasminogen activator antigen, plasminogen activator inhibitor-1 antigen, tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor were analysed at study start, after 2 years and at the end of the study (median follow-up of 6.2 years). Results: Of 129 patients (mean age of 64 ± 7 years, females: 19%), 68 (53%) and 61 (47%) were randomized to the insulin glargine and standard care group, respectively. Allocation to insulin glargine did not significantly affect the studied fibrinolytic markers or von Willebrand factor compared to standard care. Likewise, there were no significant differences in plasminogen activator inhibitor-1, tissue plasminogen activator antigen and von Willebrand factor. During the whole study period, the within-group analysis revealed a curvilinear pattern and significant changes for tissue plasminogen activator/plasminogen activator inhibitor-1 complex, tissue plasminogen activator antigen and von Willebrand factor in the insulin glargine but not in the standard care group. Conclusion: In people with dysglycaemia and other cardiovascular risk factors, basal insulin does not improve the levels of markers of fibrinolysis or von Willebrand factor compared to standard glucose-lowering treatments.
  •  
3.
  • Aidas, Kestutis, et al. (författare)
  • The Dalton quantum chemistry program system
  • 2014
  • Ingår i: WILEY INTERDISCIPLINARY REVIEWS-COMPUTATIONAL MOLECULAR SCIENCE. - Wiley. - 1759-0876. ; 4:3, s. 269-284
  • Tidskriftsartikel (refereegranskat)abstract
    • Dalton is a powerful general-purpose program system for the study of molecular electronic structure at the Hartree-Fock, Kohn-Sham, multiconfigurational self-consistent-field, MOller-Plesset, configuration-interaction, and coupled-cluster levels of theory. Apart from the total energy, a wide variety of molecular properties may be calculated using these electronic-structure models. Molecular gradients and Hessians are available for geometry optimizations, molecular dynamics, and vibrational studies, whereas magnetic resonance and optical activity can be studied in a gauge-origin-invariant manner. Frequency-dependent molecular properties can be calculated using linear, quadratic, and cubic response theory. A large number of singlet and triplet perturbation operators are available for the study of one-, two-, and three-photon processes. Environmental effects may be included using various dielectric-medium and quantum-mechanics/molecular-mechanics models. Large molecules may be studied using linear-scaling and massively parallel algorithms. Dalton is distributed at no cost from for a number of UNIX platforms.
  •  
4.
  • Agewall, Stefan, et al. (författare)
  • Efterlyses : politik mot hjärtinfarkt
  • 2013
  • Ingår i: Läkartidningen. - Stockholm : Sveriges läkarförbund. - 0023-7205. ; 110:13-14, s. 664
  • Tidskriftsartikel (refereegranskat)abstract
    • Medicinen kommer inte så mycket längre när det gäller att minska dödligheten i hjärt–kärlsjukdomar. Framtidens utmaning ligger i att förhindra att människor alls insjuknar i hjärtinfarkt. Författarna efterlyser politiska åtgärder som gör de hälsosamma valen billiga och attraktiva.
  •  
5.
  • Alvariza, Anette, et al. (författare)
  • Family members' experiences of integrated palliative advanced home and heart failure care : a qualitative study of the PREFER intervention
  • 2017
  • Ingår i: Palliative & Supportive Care. - New York : Cambridge University Press. - 1478-9515.
  • Tidskriftsartikel (refereegranskat)abstract
    • Chronic heart failure is a disease with high morbidity and symptom burden for patients, and it also places great demands on family members. Patients with heart failure should have access to palliative care for the purpose of improving quality of life for both patients and their families. In the PREFER randomized controlled intervention, patients with New York Heart Association classes III–IV heart failure received person-centered care with a multidisciplinary approach involving collaboration between specialists in palliative and heart failure care. The aim of the present study was to describe family members' experiences of the intervention, which integrated palliative advanced home and heart failure care.Method: This study had a qualitative descriptive design based on family member interviews. Altogether, 14 family members participated in semistructured interviews for evaluation after intervention completion. The data were analyzed by means of content analysis.Results: Family members expressed gratitude and happiness after witnessing the patient feeling better due to symptom relief and empowerment. They also felt relieved and less worried, as they were reassured that the patient was being cared for properly and that their own responsibility for care was shared with healthcare professionals. However, some family members also felt as though they were living in the shadow of severe illness, without receiving any support for themselves.Significance of results: Several benefits were found for family members from the PREFER intervention, and our results indicate the significance of integrated palliative advanced home and heart failure care. However, in order to improve this intervention, psychosocial professionals should be included on the intervention team and should contribute by paying closer attention and providing targeted support for family members.
  •  
6.
  • Andersson, Jonas, 1977-, et al. (författare)
  • C-reactive protein is a determinant of first-ever stroke : prospective nested case-referent study
  • 2009
  • Ingår i: Cerebrovascular Diseases. - 1015-9770. ; 27:6, s. 544-551
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND AND PURPOSE: C-reactive protein (CRP) is a determinant of stroke, but there are no prospective studies on CRP and first ischemic stroke divided into etiologic subtypes. Our primary aim was to study CRP as a determinant of ischemic stroke, classified according to Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria, and intracerebral hemorrhage (ICH) in a prospective study. A secondary aim was to study the relationship between the 1444C>T polymorphism, plasma levels of CRP and stroke.METHODS: The study was a prospective population-based case-referent study nested within the Northern Sweden Cohorts. We defined 308 cases of ischemic stroke and 61 ICH. Two controls for each case were defined from the same cohort.RESULTS: The OR for the highest (>3 mg/l) versus lowest group (<1 mg/l) of CRP was 2.58 (95% CI 1.74-3.84) for ischemic stroke and 1.63 (95% CI 0.67-3.93) for ICH. In a multivariate model including traditional risk factors, CRP remained associated with ischemic stroke (OR 2.06; 95% CI 1.29-3.29). Small-vessel disease was associated with CRP in the multivariate model (OR 3.88; 95% CI 1.10-13.7). The CRP 1444 (CC/CT vs. TT) polymorphism was associated with plasma levels of CRP but neither with ischemic stroke nor with ICH.CONCLUSIONS: This prospective population-based study shows that CRP is significantly associated with the risk of having a first ischemic stroke, especially for small-vessel disease. No significant associations were found between the CRP 1444C>T polymorphism and any stroke subtype.
  •  
7.
  • Andersson, Jonas, 1977-, et al. (författare)
  • Effect of intensive lifestyle intervention on C-reactive protein in subjects with impaired glucose tolerance and obesity : results from a randomized controlled trial with 5-year follow-up
  • 2008
  • Ingår i: Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals. - 1366-5804. ; 13:7, s. 671-679
  • Tidskriftsartikel (refereegranskat)abstract
    • C-reactive protein (CRP) is a marker of metabolic and cardiovascular disease. To study the effects of lifestyle on CRP in a high-risk population we conducted a randomized controlled trial on 200 obese subjects (BMI > 27 kg m(-2)) with impaired glucose tolerance recruited from primary care settings. They were randomized to either a 1-month stay at a wellness centre focusing on diet, exercise and stress management (intervention group) or 30-60 min of oral and written information on lifestyle intervention (control group). A significant reduction of CRP was observed after 1 month and 1 year in the intervention group. They reduced their CRP levels more than the control group 1 year after intervention (p=0.004). In conclusion lifestyle intervention can decrease CRP in obese individuals with impaired glucose tolerance for up to 1 year. Further research is needed to evaluate whether the CRP level reduction translates into a decreased risk for cardiovascular morbidity.
  •  
8.
  • Andersson, Jonas, 1977-, et al. (författare)
  • Effects of heavy endurance physical exercise on inflammatory markers in non-athletes
  • 2010
  • Ingår i: Atherosclerosis. - 0021-9150. ; 209:2, s. 601-605
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVES: Physical activity has beneficial effects on cardiovascular disease but the mechanisms are still somewhat unclear. One possible pathway may be through the anti-inflammatory effects attributed to regular physical activity. Our primary aim was to study the effects of endurance physical exercise on C-reactive protein (CRP), Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNFalpha) during the acute and recovery phases. Secondarily, we studied the impact of diet on these inflammatory markers.METHODS: Twenty men, aged 18-55 years, participated in a 14 days cross-country skiing tour. They traveled 12-30km per day corresponding to about 10h of heavy physical activity. The participants were randomized to a diet with either 30 or 40% of energy derived from fat. Inflammatory variables were analysed at week 0, after 1 and 2 weeks and during the recovery phase at week 6 and 8.RESULTS: CRP and TNFalpha increased significantly during the two weeks of exercise (1.4-5.0mg/l, p=0.00 and 6.8-8.4pg/ml, p=0.00). CRP levels were significantly lower during recovery (median 0.7mg/l) compared to baseline (median 1.4mg/l) and did not correlate to metabolic variables. There were no significant changes in IL-6 levels during the study period. For dietary groups significant CRP changes were observed only in the high fat group during recovery.CONCLUSIONS: CRP and TNFalpha increased significantly but reacted differently during heavy physical activity while there seemed to be no significant changes in IL-6. No significant differences regarding inflammatory variables were found between the dietary groups.
  •  
9.
  •  
10.
  • Bang, Casper N., et al. (författare)
  • Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis : The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study
  • 2012
  • Ingår i: American Heart Journal. - Elsevier. - 0002-8703. ; 163:4, s. 690-696
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Lipid-lowering drugs, particularly statins, have anti-inflammatory and antioxidant properties that may prevent atrial fibrillation (AF). This effect has not been investigated on new-onset AF in asymptomatic patients with aortic stenosis (AS). Methods Asymptomatic patients with mild-to-moderate AS (n = 1,421) were randomized (1: 1) to double-blind simvastatin 40 mg and ezetimibe 10 mg combination or placebo and followed up for a mean of 4.3 years. The primary end point was the time to new-onset AF adjudicated by 12-lead electrocardiogram at a core laboratory reading center. Secondary outcomes were the correlates of new-onset AF with nonfatal nonhemorrhagic stroke and a combined end point of AS-related events. Results During the course of the study, new-onset AF was detected in 85 (6%) patients (14.2/1,000 person-years of follow-up). At baseline, patients who developed AF were, compared with those remaining in sinus rhythm, older and had a higher left ventricular mass index a smaller aortic valve area index. Treatment with simvastatin and ezetimibe was not associated with less new-onset AF (odds ratio 0.89 [95% CI 0.57-1.97], P = .717). In contrast, age (hazard ratio [HR] 1.07 [95% CI 1.05-1.10], P < .001) and left ventricular mass index (HR 1.01 [95% CI 1.01-1.02], P < .001) were independent predictors of new-onset AF. The occurrence of new-onset AF was independently associated with 2-fold higher risk of AS-related outcomes (HR 1.65 [95% CI 1.02-2.66], P = .04) and 4-fold higher risk of nonfatal nonhemorrhagic stroke (HR 4.04 [95% CI 1.18-13.82], P = .03). Conclusions Simvastatin and ezetimibe were not associated with less new-onset AF. Older age and greater left ventricular mass index were independent predictors of AF development. New-onset AF was associated with a worsening of prognosis. (Am Heart J 2012;163:690-6.)
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 189
Åtkomst
fritt online (16)
Typ av publikation
tidskriftsartikel (175)
annan publikation (7)
konferensbidrag (5)
doktorsavhandling (1)
bokkapitel (1)
Typ av innehåll
refereegranskat (155)
övrigt vetenskapligt (33)
populärvet., debatt m.m. (1)
Författare/redaktör
Boman, Kurt (185)
Wachtell, Kristian (51)
Gerdts, Eva (42)
Devereux, Richard B (31)
Jansson, Jan-Håkan, (24)
Willenheimer, Ronnie ... (24)
visa fler...
Ray, Simon (22)
Olofsson, Mona, (22)
Gohlke-Baerwolf, Chr ... (20)
Dahlöf, Björn (19)
Brännström, Margaret ... (18)
Egstrup, Kenneth (17)
Nilsson, Torbjörn K (15)
Pedersen, Terje R., (15)
Nienaber, Christoph ... (15)
Nieminen, Markku S. (14)
Rossebo, Anne B. (14)
Johansson, Lars, (12)
Greve, Anders M. (12)
Holme, Ingar (11)
Dahlström, Ulf, (11)
de Simone, Giovanni (11)
Chambers, John B (11)
Kober, Lars (10)
Wachtell, K. (10)
Bang, Casper N. (10)
Papademetriou, Vasil ... (10)
Wikstrom, G. (9)
Hallmans, Göran, (9)
Stålhammar, Jan, (9)
Stalhammar, J (9)
Gohlke-Bärwolf, Chri ... (9)
Okin, Peter M (9)
Malbecq, William (9)
Skjærpe, Terje (9)
Wikström, Gerhard, (8)
Ekman, Inger, (8)
Olsen, Michael H (8)
Kesaniemi, Y Antero (8)
Tornblom, M, (7)
Weinehall, Lars (7)
Kesäniemi, Y Antero (7)
Bergman, G. J. (7)
Brudi, Philippe (7)
Alehagen, Urban, (6)
Stenlund, Hans (6)
Strandberg, Gunilla, (6)
Löfgren, Britta, (6)
Swedberg, Karl, (6)
Lindmark, K., (6)
visa färre...
Lärosäte
Umeå universitet (173)
Göteborgs universitet (26)
Lunds universitet (22)
Uppsala universitet (20)
Linköpings universitet (8)
Örebro universitet (6)
visa fler...
Karolinska Institutet (4)
Ersta Sköndal Bräcke högskola (3)
Linnéuniversitetet (2)
Kungliga Tekniska Högskolan (1)
Sophiahemmet Högskola (1)
visa färre...
Språk
Engelska (165)
Svenska (15)
Odefinierat språk (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (158)
Naturvetenskap (2)
Teknik (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy